Efficacy, safety of switching to latanoprostene bunod 0.024% in patients with OAG and OHT
Ophthalmology Times,
The switch may produce an additional 25% IOP reduction in mild to moderate forms of disease (Image Credit: AdobeStock/Davizro…
The switch may produce an additional 25% IOP reduction in mild to moderate forms of disease (Image Credit: AdobeStock/Davizro…
First Prostaglandin Analog with one of its Metabolites Being Nitric Oxide Approved to Provide Consistent and Sustained IOP…
/PRNewswire/ -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb…
Information contained on this page is provided by an independent third-party content provider.